Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 2/20 | 0.47 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.47 |
| ▸ | ITGAL | P20701 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10122812 | 1.00 | ITGB2 (0.47) | ITGB2ICAM1ITGALHRH3HRH4 | |
| SCHEMBL19364755 | 0.88 | HRH3 (0.48) | ITGB2ICAM1ITGALHRH3HRH4 | |
| SCHEMBL19364630 | 0.86 | HRH3 (0.50) | ITGB2ICAM1ITGALHRH3HRH4 | |
| SCHEMBL14961160 | 0.86 | ITGB2 (0.49) | ITGB2ICAM1ITGALHRH3HRH4 | |
| SCHEMBL14961161 | 0.86 | ITGB2 (0.49) | ITGB2ICAM1ITGALHRH3HRH4 | |
| SCHEMBL6806998 | 0.86 | ITGB2 (0.62) | ITGB2ICAM1ITGALALDH1A1CYP1A2 | |
| SCHEMBL13187470 | 0.86 | ITGB2 (0.49) | ITGB2ICAM1ITGALHRH3HRH4 | |
| SCHEMBL12979930 | 0.84 | ITGB2 (0.47) | ITGB2ICAM1ITGALHRH3HRH4 | |
| SCHEMBL8906903 | 0.83 | HRH3 (0.47) | ITGB2ICAM1ITGALHRH3HRH4 | |
| SCHEMBL23387015 | 0.81 | HRH3 (0.47) | ITGB2ICAM1ITGALHRH3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9676802-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676802-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-9156818-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9127021-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-9000020-B2 | Linked dibenzimidazole antivirals | ENANTA PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100226882-A1 | LINKED DIIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100221216-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| WO-2010096462-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC (US) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010091413-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | ITGB2 3816/4885ICAM1 2684/4885ITGAL 3376/4885 |
| US-20100226882-A1 | LINKED DIIMIDAZOLE ANTIVIRALS | EIF2AK2, ZC3HAV1, MAVS | ITGB2 4392/4885ICAM1 1228/4885ITGAL 4256/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | ITGB2 4312/4885ICAM1 1590/4885ITGAL 3614/4885 |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | ITGB2 3816/4885ICAM1 2684/4885ITGAL 3376/4885 |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | ITGB2 3816/4885ICAM1 2378/4885ITGAL 3801/4885 |
| US-10017499-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | ITGB2 3562/4885ICAM1 2070/4885ITGAL 3006/4885 |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | ITGB2 3765/4885ICAM1 939/4885ITGAL 3955/4885 |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | ITGB2 3816/4885ICAM1 2378/4885ITGAL 3801/4885 |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | EIF2AK2, ZC3HAV1, NSUN2 | ITGB2 4395/4885ICAM1 2681/4885ITGAL 4162/4885 |
| US-20100221216-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | ITGB2 4312/4885ICAM1 1590/4885ITGAL 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.